Daptomycin-Nonsusceptible, Vancomycin-Intermediate, Methicillin-ResistantStaphylococcus aureusEndocarditis | Zendy

Ryan Yu | Zendy; Suzanne E. Dale | Zendy; Deborah Yamamura | Zendy; Vida Stankus | Zendy; Christine U. Lee | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Daptomycin-Nonsusceptible, Vancomycin-Intermediate, Methicillin-ResistantStaphylococcus aureusEndocarditis

Author(s) -

Ryan Yu,

Suzanne E. Dale,

Deborah Yamamura,

Vida Stankus,

Christine U. Lee

Publication year - 2012

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 38

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2012/138470

Subject(s) - daptomycin , vancomycin , methicillin resistant staphylococcus aureus , staphylococcus aureus , microbiology and biotechnology , endocarditis , medicine , biology , bacteria , genetics

Due to the emergence of Staphylococcus aureus with reduced vancomycin susceptibility, newer antibiotics, including daptomycin, have been used to treat methicillin-resistant S aureus infections. Daptomycin is a cyclic lipopeptide that is approved to treat S aureus bacteremia and right-sided endocarditis, and reports of S aureus with reduced susceptibility to daptomycin are infrequent. To our knowledge, the present report describes the first Canadian case of daptomycin-nonsusceptible, vancomycin-intermediate S aureus infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research